The results revealed significant differences at each H&Y stage (74.7%, 84.2%, 87.2%, 94.8%, respectively, p = 0.000, Fig. 3C), which suggested that salivary oligomeric α-synuclein might be a potential biomarker for disease progression monitoring of PD patients. The gene discussed is SNCA; the disease is Parkinson disease.